References
- Helming KC, Wang X, Roberts CW. Vulnerabilities of mutant swi/snf complexes in cancer. Cancer Cell. 2014;26(3):309–317.
- Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian swi/snf complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592–601.
- Leiserson MD, Vandin F, Wu HT, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet. 2015;47(2):106–114.
- Kadoch C, Crabtree GR. Mammalian swi/snf chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci Adv. 2015;1(5):e1500447.
- Margol AS, Judkins AR. Pathology and diagnosis of smarcb1-deficient tumors. Cancer Genet. 2014;207(9):358–364.
- Darr J, Klochendler A, Isaac S, et al. Phosphoproteomic analysis reveals smarcb1 dependent egfr signaling in malignant rhabdoid tumor cells. Mol Cancer. 2015;14:167.
- Kuwahara Y, Hosoi H, Osone S, et al. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res. 2004;10(17):5940–5948.
- Singh A, Lun X, Jayanthan A, et al. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (cns atrt): favorable activity of targeting egfr- erbb2 signaling with lapatinib. Mol Oncol. 2013;7(3):497–512.
- Wohrle S, Weiss A, Ito M, et al. Fibroblast growth factor receptors as novel therapeutic targets in snf5-deleted malignant rhabdoid tumors. PLoS One. 2013;8(10):e77652.
- Wong JP, Todd JR, Finetti MA, et al. Dual targeting of pdgfra and fgfr1 displayes synergistic efficacy in malignant rhabdoid tumors. Cell Rep. 2016;17(5):1265–1275.
- D’Cunja J, Shalaby T, Rivera P, et al. Antisense treatment of igf-ir induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer. 2007;43(10):1581–1589.
- Brenca M, Rossi S, Lorenzetto E, et al. Smarcb1/ini1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line vaesbj. Mol Cancer Ther. 2013;12(6):1060–1072.
- Tan A-C, Vyse S, Huang PH. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today. 2016. doi: 10.1016/j.drudis.2016.07.010.
- Xu AM, Huang PH. Receptor tyrosine kinase coactivation networks in cancer. Cancer Res. 2010;70(10):3857–3860.
- Papadakis AI, Sun C, Knijnenburg TA, et al. Smarce1 suppresses egfr expression and controls responses to met and alk inhibitors in lung cancer. Cell Res. 2015;25(4):445–458.
- Fillmore CM, Xu C, Desai PT, et al. Ezh2 inhibition sensitizes brg1 and egfr mutant lung tumours to topoii inhibitors. Nature. 2015;520(7546):239–242.
- Miller RE, Brough R, Bajrami I, et al. Synthetic lethal targeting of arid1a-mutant ovarian clear cell tumors with dasatinib. Mol Cancer Ther. 2016;15(7):1472–1484.
- Noujaim J, Payne LS, Judson I, et al. Phosphoproteomics in translational research: a sarcoma perspective. Ann Oncol. 2016;27(5):787–794.
- Tan AC, Ryall KA, Huang PH. Expanding the computational toolbox for interrogating cancer kinomes. Pharmacogenomics. 2016;17(2):95–97.
- Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012;122(8):2983–2988.
- Johann PD, Erkek S, Zapatka M, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell. 2016;29(3):379–393.
- Chandler RL, Damrauer JS, Raab JR, et al. Coexistent arid1a-pik3ca mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun. 2015;6:6118.
- Wu Q, Sharma S, Cui H, et al. Targeting the chromatin remodeling enzyme brg1 increases the efficacy of chemotherapy drugs in breast cancer cells. Oncotarget. 2016;7(19):27158–27175.